§01 Browse › IGF-1 DES

IGF-1 DES

Des(1-3)IGF-1 DES IGF-1 Truncated IGF-1
Recovery

None

Technical catalog description

IGF-1 DES is a truncated form of IGF-1 that lacks the first three amino acids of the standard molecule. This deletion removes the binding sites for IGF-binding proteins (IGFBPs), meaning DES reaches the receptor unimpeded and is approximately 10× more potent than standard IGF-1 at the receptor level.

The trade-off is a very short half-life, under 20 minutes, which severely limits systemic distribution and makes it almost exclusively a site-injection compound. Bodybuilders use it for local muscle stimulation, injecting directly into trained muscle post-workout to drive localized hyperplasia and satellite cell activation. The systemic insulin-like effects are less prominent than with IGF-1 LR3, but the local potency at the injection site is dramatically higher.

Overview Use context Comparison Safety
Warning
Requires acetic acid reconstitution for stability, not bacteriostatic water · Very short half-life means timing is critical, so inject close to workout completion · 10× receptor potency means dose accuracy matters more than with LR3 · Hypoglycemia risk exists despite predominantly local mechanism

Read next

The Philosophy and Practice of Harm Reduction 9 min readInjection Basics and Site Safety 13 min read
Overview

IGF-1 DES is a niche compound even within the already-niche IGF-1 category. Users discuss site-specific effects, but this catalog does not validate a local injection site or workout-based administration schedule.

This matters practically. Unlike IGF-1 LR3, which has a 20-hour half-life and circulates systemically, DES lives and dies in the tissue it is injected into. Bodybuilders who use it are typically trying to address a lagging muscle group or amplify the hyperplasia response in a priority area. Most users are already advanced and have exhausted simpler interventions.

Safety & monitoring
Side effects

  • Hypoglycemia risk if dose is high or systemic distribution occurs unexpectedly

  • Local tissue swelling and temporary discomfort at injection sites

Monitoring

  • blood glucose

  • blood glucose around injection timing

  • IGF-1 serum levels if monitoring systemic activity

Avoid if

  • Users who cannot monitor blood glucose reliably around injections

  • Anyone expecting systemic body-composition effects. This is a site-specific tool.

Use context

The primary use case is local hyperplasia and site enhancement. Users who believe, or hope, that satellite cell activation in a specific muscle can be pushed higher than training alone achieves find the mechanism compelling. The 10× receptor potency is real. What varies is whether the practical result in an individual user lives up to the theory.

Timeline & expectations

If it works as intended, local fullness and better site responsiveness over the cycle period are the expected feedback. Dramatic visual size change from a few weeks of site injections is overstated in older bodybuilding culture. The result, when it shows up, is usually incremental.

Common mistakes

Applying a preparation or injection protocol based on a generic peptide name. This profile does not validate reconstitution instructions, injection sites, or administration timing.

Comparison notes

Compared with IGF-1 LR3, DES has dramatically higher receptor potency but zero systemic duration. They serve different purposes: LR3 for systemic recovery and growth signaling, DES for localized hyperplasia work in specific sites. Stacking them is done by some advanced users to try to capture both mechanisms simultaneously.

Record quantities in the builder Read: The Philosophy and Practice of Harm Reduction ← Browse